POSACONAZOLE DELAYED RELEASE

N/A

Manufactured by A2A Integrated Pharmaceuticals

20,089 FDA adverse event reports analyzed

Last updated: 2026-04-14

About POSACONAZOLE DELAYED RELEASE

POSACONAZOLE DELAYED RELEASE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by A2A Integrated Pharmaceuticals. The most commonly reported adverse reactions for POSACONAZOLE DELAYED RELEASE include DRUG INEFFECTIVE, OFF LABEL USE, FEBRILE NEUTROPENIA, DRUG INTERACTION, PYREXIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for POSACONAZOLE DELAYED RELEASE.

Top Adverse Reactions

DRUG INEFFECTIVE1,266 reports
OFF LABEL USE1,106 reports
FEBRILE NEUTROPENIA854 reports
DRUG INTERACTION729 reports
PYREXIA620 reports
NEUTROPENIA616 reports
DEATH542 reports
PRODUCT USE IN UNAPPROVED INDICATION486 reports
PNEUMONIA462 reports
THROMBOCYTOPENIA391 reports
DIARRHOEA356 reports
SEPTIC SHOCK349 reports
CONDITION AGGRAVATED326 reports
NAUSEA321 reports
ACUTE KIDNEY INJURY306 reports
SEPSIS303 reports
PANCYTOPENIA289 reports
FATIGUE275 reports
DISEASE PROGRESSION237 reports
RESPIRATORY FAILURE229 reports
ANAEMIA225 reports
ASPERGILLUS INFECTION213 reports
VOMITING210 reports
DYSPNOEA209 reports
INFECTION206 reports
ACUTE MYELOID LEUKAEMIA204 reports
ASTHENIA202 reports
HYPOKALAEMIA198 reports
BRONCHOPULMONARY ASPERGILLOSIS197 reports
GRAFT VERSUS HOST DISEASE192 reports
PLATELET COUNT DECREASED187 reports
TOXICITY TO VARIOUS AGENTS183 reports
HEADACHE181 reports
RENAL FAILURE179 reports
FUNGAL INFECTION178 reports
DRUG RESISTANCE169 reports
MUCORMYCOSIS169 reports
HYPOTENSION164 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME162 reports
PRODUCT USE ISSUE151 reports
PNEUMONIA FUNGAL147 reports
TREATMENT FAILURE144 reports
ELECTROCARDIOGRAM QT PROLONGED143 reports
CYTOKINE RELEASE SYNDROME137 reports
DECREASED APPETITE132 reports
ACUTE MYELOID LEUKAEMIA RECURRENT131 reports
COVID 19130 reports
RASH125 reports
BACTERAEMIA124 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION124 reports
CYTOMEGALOVIRUS INFECTION REACTIVATION121 reports
CYTOPENIA121 reports
RENAL IMPAIRMENT121 reports
WHITE BLOOD CELL COUNT DECREASED121 reports
ABDOMINAL PAIN119 reports
PLEURAL EFFUSION118 reports
CONSTIPATION115 reports
COUGH114 reports
HYPOXIA113 reports
MYELOSUPPRESSION110 reports
STAPHYLOCOCCAL INFECTION108 reports
PSEUDOMONAS INFECTION107 reports
URINARY TRACT INFECTION107 reports
PAIN106 reports
CYTOMEGALOVIRUS INFECTION105 reports
DEVICE RELATED INFECTION105 reports
HAEMOGLOBIN DECREASED105 reports
HEPATIC CYTOLYSIS105 reports
DIZZINESS104 reports
HYPERTENSION104 reports
MUCOSAL INFLAMMATION104 reports
GENERAL PHYSICAL HEALTH DETERIORATION103 reports
FUSARIUM INFECTION100 reports
ENCEPHALOPATHY99 reports
CARDIAC ARREST97 reports
HEPATOTOXICITY97 reports
CANDIDA INFECTION95 reports
WEIGHT DECREASED94 reports
BONE MARROW FAILURE93 reports
TACHYCARDIA91 reports
CHOLESTASIS90 reports
MUSCULAR WEAKNESS90 reports
HAEMORRHAGE89 reports
NEUROTOXICITY89 reports
NEUTROPHIL COUNT DECREASED89 reports
CELLULITIS88 reports
FALL88 reports
NEUROPATHY PERIPHERAL87 reports
BACTERIAL INFECTION86 reports
ALANINE AMINOTRANSFERASE INCREASED84 reports
ENTEROCOCCAL INFECTION84 reports
HYPERBILIRUBINAEMIA84 reports
PATHOGEN RESISTANCE84 reports
GRAFT VERSUS HOST DISEASE IN GASTROINTESTINAL TRACT83 reports
SYSTEMIC CANDIDA83 reports
TUMOUR LYSIS SYNDROME83 reports
BLOOD CREATININE INCREASED82 reports
CHRONIC GRAFT VERSUS HOST DISEASE82 reports
DRUG INTOLERANCE82 reports
ATRIAL FIBRILLATION81 reports

Report Outcomes

Out of 10,172 classified reports for POSACONAZOLE DELAYED RELEASE:

Serious 92.9%Non-Serious 7.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male5,397 (60.1%)
Female3,540 (39.4%)
Unknown42 (0.5%)

Reports by Age

Age 67208 reports
Age 70208 reports
Age 65206 reports
Age 68203 reports
Age 59195 reports
Age 63194 reports
Age 49186 reports
Age 58184 reports
Age 72172 reports
Age 71171 reports
Age 64167 reports
Age 66160 reports
Age 62154 reports
Age 55153 reports
Age 56150 reports
Age 60149 reports
Age 73149 reports
Age 74148 reports
Age 53140 reports
Age 61139 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with POSACONAZOLE DELAYED RELEASE?

This profile reflects 20,089 FDA FAERS reports that mention POSACONAZOLE DELAYED RELEASE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for POSACONAZOLE DELAYED RELEASE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, FEBRILE NEUTROPENIA, DRUG INTERACTION, PYREXIA, NEUTROPENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures POSACONAZOLE DELAYED RELEASE?

Labeling and FAERS entries often list A2A Integrated Pharmaceuticals in connection with POSACONAZOLE DELAYED RELEASE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.